|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 982.22 USD | -1.54% |
|
-6.11% | +27.23% |
| 05:51am | Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix… |  |
| 05:54am | French biotech Abivax's shares climb on Eli Lilly bid rumors | RE |
| Capitalization | 879B 756B 709B 661B 1,216B 79,021B 1,322B 8,221B 3,195B 37,454B 3,300B 3,230B 137,998B | P/E ratio 2025 * |
42.9x | P/E ratio 2026 * | 31x |
|---|---|---|---|---|---|
| Enterprise value | 904B 777B 729B 679B 1,251B 81,262B 1,360B 8,454B 3,286B 38,516B 3,394B 3,322B 141,913B | EV / Sales 2025 * |
14.2x | EV / Sales 2026 * | 11.7x |
| Free-Float |
99.81% | Yield 2025 * |
0.6% | Yield 2026 * | 0.68% |
Last Transcript: Eli Lilly and Company
| 1 day | -0.26% | ||
| 1 week | -6.11% | ||
| Current month | -8.67% | ||
| 1 month | +6.26% | ||
| 3 months | +30.86% | ||
| 6 months | +26.95% | ||
| Current year | +27.23% |
| 1 week | 979.18 |  | 1,032.62 |
| 1 month | 965.28 | | 1,111.99 |
| Current year | 623.78 | | 1,111.99 |
| 1 year | 623.78 | | 1,111.99 |
| 3 years | 302.14 | | 1,111.99 |
| 5 years | 157.83 | | 1,111.99 |
| 10 years | 64.18 | | 1,111.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 57 | 2016-12-31 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 48 | 2024-09-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 65 | 2004-12-31 |
Ralph Alvarez
BRD | Director/Board Member | 69 | 2009-03-31 |
| Director/Board Member | 53 | 2011-12-11 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 6.49% | 26 M€ | +11.19% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.54% | -6.11% | +22.23% | +172.09% | 879B | |
| -0.82% | -2.66% | +33.66% | +13.78% | 482B | |
| -0.06% | -0.62% | +26.29% | +36.75% | 394B | |
| -1.03% | -0.61% | +22.89% | +2.94% | 335B | |
| -0.29% | -1.02% | +28.94% | +19.42% | 281B | |
| -1.39% | -2.09% | +18.48% | +23.82% | 254B | |
| -2.06% | -4.10% | -6.65% | -10.93% | 240B | |
| +1.31% | +0.21% | -61.09% | -33.29% | 207B | |
| -2.30% | -7.24% | +13.05% | +12.63% | 169B | |
| -1.51% | -3.67% | +31.76% | +35.68% | 148B | |
| Average | -0.86% | -2.72% | +12.96% | +27.29% | 338.97B | |
| Weighted average by Cap. | -0.71% | -3.02% | +17.48% | +53.94% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 63.58B 54.63B 51.25B 47.75B 87.94B 5,713B 95.57B 594B 231B 2,708B 239B 234B 9,976B | 75.89B 65.2B 61.17B 57B 105B 6,819B 114B 709B 276B 3,232B 285B 279B 11,908B |
| Net income | 20.4B 17.53B 16.44B 15.32B 28.22B 1,833B 30.66B 191B 74.11B 869B 76.55B 74.93B 3,201B | 27.9B 23.97B 22.49B 20.95B 38.59B 2,507B 41.94B 261B 101B 1,188B 105B 102B 4,378B |
| Net Debt | 24.95B 21.43B 20.11B 18.74B 34.51B 2,241B 37.5B 233B 90.63B 1,062B 93.61B 91.63B 3,914B | 10.94B 9.4B 8.81B 8.21B 15.13B 983B 16.44B 102B 39.73B 466B 41.04B 40.17B 1,716B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-09 | 982.22 $ | -1.54% | 2,569,724 |
| 25-12-08 | 997.59 $ | -1.26% | 3,088,557 |
| 25-12-05 | 1,010.31 $ | -0.41% | 2,502,066 |
| 25-12-04 | 1,014.49 $ | -1.85% | 3,854,911 |
| 25-12-03 | 1,033.56 $ | -1.20% | 3,447,003 |
Delayed Quote Nyse, December 09, 2025 at 04:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition